EDVA

Análisis de la acción EDVA (EDVA)

$0.264

-0.004 (-1.68%)Al cierre

Loading chart…
High
0.278
Open
0.278
VWAP
0.27
Vol
73.52K
Mkt Cap
Low
0.263
Amount
19.74K
EV/EBITDA, TTM
0.00

Endovia Health Sciences, Inc., formerly Splash Beverage Group, Inc. seeks to identify, acquire, and build early stage or under-valued beverage brands that have growth potential within its distribution system. The Company’s distribution system is comprehensive in the United States and is expanding to select international markets. Through its division Qplash, Splash’s distribution reach includes e-commerce access to both business-to-business (B2B) and business-to-consumer (B2C) customers. It markets beverage brands to customers throughout the United States that prefer delivery direct to their office, facilities, or homes. Its segments include Splash Beverage Group and E-Commerce. The Company's Splash Beverage Group segment includes the manufacture and distribution of non-alcoholic and alcoholic branded beverages. The E-commerce segment is engaged in the sale of e-commerce beverages. Its brands include Copa di Vino single-serve wine, Pulpoloco Sangria, SALT Tequila, and Chispo Tequila.

AI analysis of EDVA (EDVA)

sell

Endovia Health Sciences, Inc. is not a good buy right now due to significant financial losses and poor performance metrics. The current price is 0.26, and the company has a staggering net income loss of -4719563 in Q3 2024, indicating ongoing financial distress. Additionally, the stock has dropped 44.01% year-to-date, reflecting a lack of investor confidence and potential long-term viability issues.

Métricas de valoración

The current forward P/E ratio for EDVA (EDVA) is 0.00, compared to its 5-year average forward P/E of .

Forward P/E

5Y Average P/E
Current P/E
0.00

Forward EV/EBITDA

5Y Average EV/EBITDA
Current EV/EBITDA
0.00

Forward P/S

5Y Average P/S
Current P/S
0.00

EDVA FAQ — answered by Alphio AI

Endovia Health Sciences, Inc. is not a good buy right now due to significant financial losses and poor performance metrics. The current price is 0.26, and the company has a staggering net income loss of -4719563 in Q3 2024, indicating ongoing financial distress. Additionally, the stock has dropped 44.01% year-to-date, reflecting a lack of investor confidence and potential long-term viability issues.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis